|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
1,250,000,000 |
Market
Cap: |
84.65(B) |
Last
Volume: |
3,579,101 |
Avg
Vol: |
8,731,484 |
52
Week Range: |
$64.58 - $87.29 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 259 |
Guru Rank Value : 4.6 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
12,230 |
25,472 |
38,458 |
80,792 |
Total Sell Value |
$890,904 |
$2,022,270 |
$3,052,046 |
$6,445,296 |
Total People Sold |
1 |
3 |
3 |
4 |
Total Sell Transactions |
3 |
5 |
9 |
14 |
End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Lofton Kevin E |
Director |
|
2020-05-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,270 |
88,849 |
|
- |
|
Wilson Gayle E |
Director |
|
2020-05-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,270 |
129,052 |
|
- |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2020-05-05 |
4 |
S |
$79.23 |
$1,046,640 |
D/D |
(13,210) |
14,644 |
|
18% |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2020-05-05 |
4 |
OE |
$24.30 |
$525,225 |
D/D |
13,210 |
27,854 |
|
- |
|
Wilfong Diane E |
SVP, Controller & CAO |
|
2020-05-04 |
4 |
S |
$80.09 |
$982,220 |
D/D |
(12,264) |
11,421 |
|
17% |
|
Wilfong Diane E |
SVP, Controller & CAO |
|
2020-05-04 |
4 |
OE |
$66.36 |
$762,211 |
D/D |
11,486 |
23,685 |
|
- |
|
Cogan John Francis |
Director |
|
2020-05-04 |
4 |
AS |
$81.75 |
$197,508 |
D/D |
(2,416) |
54,860 |
|
-17% |
|
Cogan John Francis |
Director |
|
2020-05-04 |
4 |
OE |
$19.63 |
$47,426 |
D/D |
2,416 |
57,276 |
|
- |
|
Cogan John Francis |
Director |
|
2020-04-27 |
4 |
AS |
$79.90 |
$192,799 |
D/D |
(2,413) |
54,860 |
|
-17% |
|
Cogan John Francis |
Director |
|
2020-04-27 |
4 |
OE |
$19.63 |
$47,367 |
D/D |
2,413 |
57,273 |
|
- |
|
Cogan John Francis |
Director |
|
2020-04-20 |
4 |
AS |
$83.00 |
$200,279 |
D/D |
(2,413) |
54,860 |
|
-20% |
|
Cogan John Francis |
Director |
|
2020-04-20 |
4 |
OE |
$19.63 |
$47,367 |
D/D |
2,413 |
57,273 |
|
- |
|
Cogan John Francis |
Director |
|
2020-04-13 |
4 |
AS |
$75.90 |
$183,147 |
D/D |
(2,413) |
54,860 |
|
-10% |
|
Cogan John Francis |
Director |
|
2020-04-13 |
4 |
OE |
$19.63 |
$47,367 |
D/D |
2,413 |
57,273 |
|
- |
|
Cogan John Francis |
Director |
|
2020-04-06 |
4 |
AS |
$79.52 |
$191,882 |
D/D |
(2,413) |
54,860 |
|
-12% |
|
Cogan John Francis |
Director |
|
2020-04-06 |
4 |
OE |
$19.63 |
$47,367 |
D/D |
2,413 |
57,273 |
|
- |
|
Cogan John Francis |
Director |
|
2020-03-30 |
4 |
AS |
$75.35 |
$181,820 |
D/D |
(2,413) |
54,860 |
|
-6% |
|
Cogan John Francis |
Director |
|
2020-03-30 |
4 |
OE |
$19.63 |
$47,367 |
D/D |
2,413 |
57,273 |
|
- |
|
Cogan John Francis |
Director |
|
2020-03-23 |
4 |
AS |
$75.27 |
$181,627 |
D/D |
(2,413) |
54,860 |
|
-4% |
|
Cogan John Francis |
Director |
|
2020-03-23 |
4 |
OE |
$19.63 |
$47,367 |
D/D |
2,413 |
57,273 |
|
- |
|
Cogan John Francis |
Director |
|
2020-03-16 |
4 |
AS |
$67.26 |
$162,298 |
D/D |
(2,413) |
54,860 |
|
7% |
|
Cogan John Francis |
Director |
|
2020-03-16 |
4 |
OE |
$19.63 |
$47,367 |
D/D |
2,413 |
57,273 |
|
- |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2020-03-10 |
4 |
AS |
$75.55 |
$222,873 |
D/D |
(2,950) |
14,644 |
|
8% |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2020-03-10 |
4 |
OE |
$24.30 |
$71,670 |
D/D |
2,950 |
17,594 |
|
- |
|
Dickinson Andrew D |
EVP, Chief Financial Officer |
|
2020-03-10 |
4 |
D |
$72.34 |
$25,753 |
D/D |
(356) |
11,400 |
|
- |
|
2499 Records found
|
|
Page 13 of 100 |
|
|